Binnopharm Group has opened its ninth representative office in Vietnam to enhance its international market presence. This will enable ongoing export growth, especially to other Southeast Asian countries like Indonesia, Malaysia, the Philippines, and Thailand.
Expanding its international presence is one of the company’s strategic goals, which will create opportunities for business growth and portfolio expansion. “These are new opportunities to find business partners, establish and build relationships with them, as well as explore investment opportunities in Vietnam and promote our products. First, over-the-counter drugs in the gastrointestinal tract are being prepared for registration,” said Rustem Muratov, CEO of Binnopharm Group.
According to him, the market of Vietnam and other countries in Southeast Asia is one of the most dynamically developing segments of the pharmaceutical industry. Today, Binnopharm Group drugs are available in 13 countries. In 2023, the company launched operations in China, creating a local structure there to work with local partners and clients. In addition, in December 2024, the company announced preparations to enter the Iraqi market, where the first deliveries are planned for the fourth quarter of 2025. The first drugs for registration and subsequent deliveries have already been identified, with an estimated annual turnover of $500,000.
